Ocular Surgery News
Treatment of a second patient cohort has begun in a U.S. clinical trial for Stargardt’s macular dystrophy, according to a press release from Advanced Cell Technology. This trial involves the injection of double the number of human embryonic stem cell-derived retinal pigment epithelium cells as the first cohort.